CA2401452A1 - Combinaison de substances antioxydantes pour le traitement de la maladie d'alzheimer - Google Patents

Combinaison de substances antioxydantes pour le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
CA2401452A1
CA2401452A1 CA002401452A CA2401452A CA2401452A1 CA 2401452 A1 CA2401452 A1 CA 2401452A1 CA 002401452 A CA002401452 A CA 002401452A CA 2401452 A CA2401452 A CA 2401452A CA 2401452 A1 CA2401452 A1 CA 2401452A1
Authority
CA
Canada
Prior art keywords
group
acid
nicotinic acid
vitamin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002401452A
Other languages
English (en)
Inventor
Uri Saragovi
Joseph Bassili
Khassam Elfarrah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COLBA R&D Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002401452A priority Critical patent/CA2401452A1/fr
Publication of CA2401452A1 publication Critical patent/CA2401452A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002401452A 2001-09-04 2002-09-04 Combinaison de substances antioxydantes pour le traitement de la maladie d'alzheimer Abandoned CA2401452A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002401452A CA2401452A1 (fr) 2001-09-04 2002-09-04 Combinaison de substances antioxydantes pour le traitement de la maladie d'alzheimer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,357,043 2001-09-04
CA002401452A CA2401452A1 (fr) 2001-09-04 2002-09-04 Combinaison de substances antioxydantes pour le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CA2401452A1 true CA2401452A1 (fr) 2003-03-04

Family

ID=4171208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002401452A Abandoned CA2401452A1 (fr) 2001-09-04 2002-09-04 Combinaison de substances antioxydantes pour le traitement de la maladie d'alzheimer

Country Status (1)

Country Link
CA (1) CA2401452A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2218453A1 (fr) * 2003-08-26 2010-08-18 Mannatech, Inc. Compositions de complements alimentaires supplementaires anti-oxydants
US7976879B2 (en) * 2005-11-04 2011-07-12 Roizen Michael F Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions
US8703812B2 (en) 2005-07-29 2014-04-22 Blanchette Rockefeller Neurosciences Institute Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
AU2011250688B2 (en) * 2005-03-03 2014-06-05 Mannatech, Incorporated Methods and compositions for modified release of nutritional supplements
US9066923B2 (en) 2002-03-07 2015-06-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's disease treatment and cognitive enhancement
US9446020B2 (en) 2002-03-07 2016-09-20 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer'S disease treatment and cognitive enhancement
US9974832B2 (en) 2007-02-09 2018-05-22 Cognitive Research Enterprises, Inc. Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
US10010584B2 (en) 2004-05-18 2018-07-03 West Virginia University Treatment of depressive disorders
WO2018178029A1 (fr) * 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pour le traitement d'états ou de maladies musculaires et/ou neurologiques dégénératifs
US10716768B2 (en) * 2016-08-11 2020-07-21 National Taiwan Normal University Method for treating abnormal B-amyloid aggregation mediated diseases
CN116808017A (zh) * 2023-07-19 2023-09-29 清华大学 非瑟酮在预防/治疗kif1a相关的神经疾病中的用途

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345685B2 (en) 2002-03-07 2016-05-24 Blanchette Rockefeller Neuroscience Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US9539235B2 (en) 2002-03-07 2017-01-10 Cognitive Research Enterprises, Inc Methods for Alzheimer's disease treatment and cognitive enhancement
US9446020B2 (en) 2002-03-07 2016-09-20 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer'S disease treatment and cognitive enhancement
US9066923B2 (en) 2002-03-07 2015-06-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's disease treatment and cognitive enhancement
EP2218453A1 (fr) * 2003-08-26 2010-08-18 Mannatech, Inc. Compositions de complements alimentaires supplementaires anti-oxydants
US10010584B2 (en) 2004-05-18 2018-07-03 West Virginia University Treatment of depressive disorders
AU2011250688B2 (en) * 2005-03-03 2014-06-05 Mannatech, Incorporated Methods and compositions for modified release of nutritional supplements
US8703812B2 (en) 2005-07-29 2014-04-22 Blanchette Rockefeller Neurosciences Institute Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
US7976879B2 (en) * 2005-11-04 2011-07-12 Roizen Michael F Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions
US9974832B2 (en) 2007-02-09 2018-05-22 Cognitive Research Enterprises, Inc. Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
US10716768B2 (en) * 2016-08-11 2020-07-21 National Taiwan Normal University Method for treating abnormal B-amyloid aggregation mediated diseases
WO2018178029A1 (fr) * 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pour le traitement d'états ou de maladies musculaires et/ou neurologiques dégénératifs
CN116808017A (zh) * 2023-07-19 2023-09-29 清华大学 非瑟酮在预防/治疗kif1a相关的神经疾病中的用途
CN116808017B (zh) * 2023-07-19 2025-10-17 清华大学 非瑟酮在预防/治疗kif1a相关的神经疾病中的用途

Similar Documents

Publication Publication Date Title
US20030158237A1 (en) Combination of antioxidant substances for the treatment of alzheimer's disease
Uddin et al. Emerging signal regulating potential of genistein against Alzheimer’s disease: a promising molecule of interest
Tiwari et al. Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative–nitrosative stress in rats
Schaffer et al. Effects of polyphenols on brain ageing and Alzheimer’s disease: focus on mitochondria
Vauzour Effect of flavonoids on learning, memory and neurocognitive performance: relevance and potential implications for Alzheimer's disease pathophysiology
Boccardi et al. Vitamin E family: role in the pathogenesis and treatment of Alzheimer's disease
Mercer et al. Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures
Khan et al. Dietary flavonoids in the management of huntington’s disease: mechanism and clinical perspective
Choi Antioxidative effects of hesperetin against 7, 12-dimethylbenz (a) anthracene-induced oxidative stress in mice
Costa et al. Modulation of paraoxonase 2 (PON2) in mouse brain by the polyphenol quercetin: a mechanism of neuroprotection?
Lin et al. Structure–activity relationship of coumarin derivatives on xanthine oxidase-inhibiting and free radical-scavenging activities
Falsaperla et al. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate
Xu et al. Green tea polyphenols inhibit cognitive impairment induced by chronic cerebral hypoperfusion via modulating oxidative stress
Wagner et al. Comparative study of quercetin and its two glycoside derivatives quercitrin and rutin against methylmercury (MeHg)-induced ROS production in rat brain slices
Wang et al. Piperine regulates glycogen synthase kinase-3β-related signaling and attenuates cognitive decline in D-galactose-induced aging mouse model
US7897637B2 (en) Methods of using flavonoids to enhance memory
Li et al. Procyanidin B2 and rutin in Ginkgo biloba extracts protect human retinal pigment epithelial (RPE) cells from oxidative stress by modulating Nrf2 and Erk1/2 signalling
Persson et al. Effect of Vaccinium myrtillus and its polyphenols on angiotensin-converting enzyme activity in human endothelial cells
Yazawa et al. Distinct mechanisms underlie distinct polyphenol-induced neuroprotection
Kim et al. Piceatannol attenuates hydrogen-peroxide-and peroxynitrite-induced apoptosis of PC12 cells by blocking down-regulation of Bcl-XL and activation of JNK
Vassallo et al. Mediterranean diet and dementia of the Alzheimer type
Wang et al. Protective effect of flavonoids on oxidative stress injury in Alzheimer’s disease
Ko et al. Hydroxylation at C4′ or C6 is essential for apoptosis-inducing activity of flavanone through activation of the caspase-3 cascade and production of reactive oxygen species
Chang et al. Structure-activity relationship of C6-C3 phenylpropanoids on xanthine oxidase-inhibiting and free radical-scavenging activities
US9486430B2 (en) Treatment of neurodegenerative disease

Legal Events

Date Code Title Description
FZDE Discontinued